June 21, 2010— Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, announced a study of obese primates treated with RM-493 showing a reversal of obesity and insulin resistance, and improvement in both heart rate and blood pressure. RM-493 is a novel peptide agonist targeting the melanocortin 4 receptor (MC4R) that is a clinical candidate for the treatment of obesity and diabetes. The study, “A Novel MC4R Agonist Reduces Body Weight and Improves Glucose Homeostasis in High Fat Diet-Induced Obese Rhesus Macaques,” was presented at the 92nd annual meeting of the Endocrine Society (ENDO 2010) in San Diego.“The goal of this study was to determine the effects of RM-493 on food intake, weight, and cardiovascular function, as well as to evaluate safety with long-term treatment,”... Rhythm's Press Release -
